KYTX Stock Forecast: Kyverna Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Kyverna Therapeutics, Inc. is $32. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kyverna Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (78): Sales and profits are climbing, and climbing faster than before.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KYTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KYTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 15 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 4 Dec 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 27 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Oct 2025 | Wells Fargo | Maintains | Overweight | — |
| 29 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Aug 2025 | William Blair | Initiates | Outperform | — |
| 27 May 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 1 Apr 2025 | Morgan Stanley | Maintains | Overweight | — |
| 20 Nov 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 15 Nov 2024 | Wells Fargo | Maintains | Overweight | — |
| 10 Oct 2024 | UBS | Initiates | Buy | — |
| 19 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 31 July 2024 | JP Morgan | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KYTX.
This page is one stock. Monday covers all of them.
KYTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KYTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kyverna Therapeutics, Inc. returned −42.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KYTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.0×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −110.7%
- Return on assets
- −54.1%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kyverna Therapeutics, Inc. has a market value of $269.3M and an enterprise value of $131.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$152.6M.
Diluted earnings per share, trailing twelve months: −$2.94.
Free cash flow in the twelve months to 30 June 2026: −$160.2M.
Kyverna Therapeutics, Inc. employs 172 people.
Data provided by Twelve Data
KYTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KYTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kyverna Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KYTX
What is the KYTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Kyverna Therapeutics, Inc. is $32, with estimates ranging from $25 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KYTX stock a buy right now?
Of the 6 analysts covering Kyverna Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyverna Therapeutics, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KYTX?
As at 21 Nov 2026, Kyverna Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).
Will KYTX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $32, and Ticker Nerd's factor model ranks Kyverna Therapeutics, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KYTX stock forecast for 2030?
No analyst covering Kyverna Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $33 over the next 12 months.
How has KYTX stock performed over the past year?
Kyverna Therapeutics, Inc. returned -42.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company’s work centers on engineered T-cell therapies, including CAR T-cell and related cell therapy approaches designed to target the immune cells that drive severe autoimmune and inflammatory conditions.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company’s work centers on engineered T-cell therapies, including CAR T-cell and related cell therapy approaches designed to target the immune cells that drive severe autoimmune and inflammatory conditions. Its current programs span multiple therapeutic areas, with particular emphasis on rheumatology and neurology, alongside research efforts in other antibody-mediated and inflammatory diseases. Kyverna Therapeutics develops product candidates for conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, stiff person syndrome, multiple sclerosis, and inflammatory bowel disease. The company’s platform combines advanced cell engineering and synthetic biology to pursue more precise immune modulation than traditional broad immunosuppressive treatments. Headquartered in Emeryville, California, Kyverna Therapeutics plays a specialized role in the biotechnology market by advancing cell-based immunology therapies for serious unmet medical needs.
CEO Mr. Warner Biddle · 172 employees · United States · https://kyvernatx.com